Sandra Nestler-Parr has extensive experience in the global biotech and pharmaceutical sector, holding senior international medical and market access roles in industry and consulting. She focuses on advising clients on issues relating to market access, pricing, outcomes research and healthcare policy for rare disease treatments and innovative technologies, particularly in areas of high unmet need. She also has a special interest in effective patient engagement strategies.
Sandra has acted as an advisor to EURORDIS and is a Trustee of the Alpha-1 UK Support Group, a patient charity for the rare genetic condition alpha-1 antitrypsin deficiency (AATD). She has been instrumental in raising the profile of AATD and patients’ unmet needs and led the process which resulted in the recent ministerial approval of a national specialised service for severe AATD across NHS England.
As the co-chair of the ISPOR (International Society of Pharmacoeconomics and Outcomes Research) Rare Disease Special Interest Group and a member of several ISPOR leadership panels, Sandra continues to undertake academic research. She is an editorial board member of the International Healthcare Journal.
Sandra holds an MPhil in biochemistry (University of Cambridge, UK), a PhD in toxicology (University of London, UK) and an MSc in health economics, management and policy (London School of Economics and Political Science, UK).